Nyxoah (Nasdaq:NYXH) announced today that it received FDA approval for its Genio neuromodulation device for treating sleep apnea.

Nyxoah said the FDA approved the company's Genio system for a subset of patients with moderate to severe obstructive sleep apnea. The system includes a wearable component, which provides patients with ...

In patients with high-risk obstructive sleep apnea (OSA), continuous positive airway pressure (CPAP) improves cardiovascular outcomes.

The risk for several adverse health outcomes, including PTSD, traumatic brain injury and anxiety, was heightened among active ...

New research indicates sleep apnea patients who use CPAP machines might face increased risk of heart attack, stroke and other heart-related health conditions.

The first oral pill for obstructive sleep apnea could be around the corner after company Apnimed reported positive results from its stage III clinical trial.

Join St. Luke’s sleep medicine specialist Joshua Hitchings, MD, as he talks about obstructive sleep apnea, its causes and the compassionate care in addressing it. Dr. Hitchings examines the ...

Currently, many people diagnosed with OSA patients require a machine that covers their nose or both the nose and mouth during sleep and delivers air through a mask to help keep their airways open.

Topline results were announced from a second phase 3 trial evaluating AD109 (aroxybutynin 2.5mg/atomoxetine 75mg) in patients with obstructive sleep apnea (OSA).

Tens of millions of people in the United States struggle with obstructive sleep apnea, a condition that occurs when the throat muscles narrow during sleep, leading to temporary pauses in breathing ...

In addition to providing oral appliances, Legacy Dental is committed to educating patients about the importance of sleep health and the impact of obstructive sleep apnea on overall well-being.